Anido Armando's Form 4 filing
Zynerba Pharmaceuticals, Inc. (ZYNE) · filed Jul 20, 2022
- Accession no.
- 0001062993-22-016555
- Filed
- Jul 20, 2022
- Trade date
- Jul 18-19, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $13.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anido ArmandoCIK 0001219866 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 18, 2022 | Common Stock | AGrant or awardAcquired | +43,164 | –F1 | – | 623,587 | Direct | |
| Jul 19, 2022 | Common Stock | SSaleDisposed | −11,899 | $1.10 | −$13,088.9 | 611,688 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 43,164 performance-based restricted stock awards granted in a prior year.
Referenced by the price of 1 transaction in Table I.